Quotient Wealth Partners LLC Acquires 145 Shares of Eli Lilly and Company (NYSE:LLY)

Quotient Wealth Partners LLC increased its stake in Eli Lilly and Company (NYSE:LLY) by 4.8% during the fourth quarter, according to the company in its most recent 13F filing with the SEC. The firm owned 3,154 shares of the company’s stock after purchasing an additional 145 shares during the quarter. Quotient Wealth Partners LLC’s holdings in Eli Lilly and Company were worth $2,435,000 at the end of the most recent quarter.

Other institutional investors and hedge funds also recently bought and sold shares of the company. Northeast Investment Management raised its stake in shares of Eli Lilly and Company by 4.3% in the fourth quarter. Northeast Investment Management now owns 53,478 shares of the company’s stock worth $41,285,000 after buying an additional 2,226 shares during the period. Summit Wealth & Retirement Planning Inc. increased its holdings in Eli Lilly and Company by 84.5% in the 4th quarter. Summit Wealth & Retirement Planning Inc. now owns 546 shares of the company’s stock worth $422,000 after acquiring an additional 250 shares in the last quarter. Investment Advisory Services Inc. TX ADV raised its stake in Eli Lilly and Company by 8.1% during the 4th quarter. Investment Advisory Services Inc. TX ADV now owns 322 shares of the company’s stock worth $248,000 after acquiring an additional 24 shares during the period. WCM Investment Management LLC lifted its holdings in Eli Lilly and Company by 26.0% during the fourth quarter. WCM Investment Management LLC now owns 16,705 shares of the company’s stock valued at $12,927,000 after purchasing an additional 3,445 shares in the last quarter. Finally, Entropy Technologies LP boosted its position in shares of Eli Lilly and Company by 113.6% in the fourth quarter. Entropy Technologies LP now owns 8,141 shares of the company’s stock worth $6,285,000 after purchasing an additional 4,329 shares during the period. 82.53% of the stock is currently owned by hedge funds and other institutional investors.

Eli Lilly and Company Trading Down 1.1 %

Shares of LLY stock opened at $868.57 on Tuesday. The company has a market cap of $824.55 billion, a PE ratio of 74.17, a price-to-earnings-growth ratio of 1.87 and a beta of 0.42. Eli Lilly and Company has a 1 year low of $711.40 and a 1 year high of $972.53. The stock’s 50 day simple moving average is $789.87 and its two-hundred day simple moving average is $843.19. The company has a debt-to-equity ratio of 2.03, a current ratio of 1.27 and a quick ratio of 0.97.

Eli Lilly and Company (NYSE:LLY) last released its quarterly earnings results on Thursday, February 6th. The company reported $5.32 earnings per share for the quarter, missing the consensus estimate of $5.45 by ($0.13). Eli Lilly and Company had a net margin of 23.51% and a return on equity of 86.26%. Research analysts predict that Eli Lilly and Company will post 23.33 earnings per share for the current year.

Eli Lilly and Company Increases Dividend

The company also recently announced a quarterly dividend, which will be paid on Monday, March 10th. Stockholders of record on Friday, February 14th will be issued a $1.50 dividend. This represents a $6.00 annualized dividend and a dividend yield of 0.69%. The ex-dividend date is Friday, February 14th. This is a positive change from Eli Lilly and Company’s previous quarterly dividend of $1.30. Eli Lilly and Company’s dividend payout ratio (DPR) is 44.41%.

Eli Lilly and Company announced that its board has authorized a share buyback program on Monday, December 9th that permits the company to repurchase $15.00 billion in outstanding shares. This repurchase authorization permits the company to purchase up to 2% of its shares through open market purchases. Shares repurchase programs are often a sign that the company’s board of directors believes its stock is undervalued.

Analyst Upgrades and Downgrades

Several analysts have recently commented on the stock. Truist Financial raised their price objective on shares of Eli Lilly and Company from $1,029.00 to $1,038.00 and gave the company a “buy” rating in a research report on Monday, February 3rd. Citigroup decreased their price target on Eli Lilly and Company from $1,250.00 to $1,190.00 and set a “buy” rating on the stock in a report on Tuesday, January 28th. Bank of America reaffirmed a “buy” rating and issued a $997.00 price objective on shares of Eli Lilly and Company in a research note on Tuesday, December 10th. Sanford C. Bernstein started coverage on Eli Lilly and Company in a research note on Thursday, October 17th. They set an “outperform” rating and a $1,100.00 target price on the stock. Finally, Deutsche Bank Aktiengesellschaft dropped their price target on Eli Lilly and Company from $1,025.00 to $1,015.00 and set a “buy” rating for the company in a research note on Monday, November 4th. Four research analysts have rated the stock with a hold rating and eighteen have assigned a buy rating to the company’s stock. According to data from MarketBeat, the company presently has an average rating of “Moderate Buy” and an average price target of $997.50.

About Eli Lilly and Company

Eli Lilly and Company discovers, develops, and markets human pharmaceuticals worldwide. The company offers Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, and Humulin U-500 for diabetes; Jardiance, Mounjaro, and Trulicity for type 2 diabetes; and Zepbound for obesity.